In a substudy of SURMOUNT-1, tirzepatide reduced ambulatory blood pressure in adults with a BMI ≥27 kg/m² compared with placebo.
In a large prospective Taiwanese cohort study, prolonged occupational sitting was associated with higher risk of mortality compared with occupational nonsitting. The associated harm of prolonged occupational sitting was attenuated by alternating between sitting and nonsitting, as well as increasing physical activity.
An 18-year prospective study suggested that higher perceived stress in adolescence and young adulthood and high stress levels over time may contribute to increased cardiometabolic risk in young adults.
In an international cross-sectional registry study, classic diagnostic features of familial hypercholesterolemia were uncommon in individuals aged <18 years, and the diagnosis therefore relied on LDL-c levels or genetic confirmation. Most participants were not on lipid-lowering therapy.
AHA 2023 In the ARTESIA trial, patients with subclinical AF were randomized to apixaban or aspirin and followed for stroke or systemic embolism and major bleeding. Jeff Healey discusses the results.
AHA 2023 Michael Lincoff shares the results of the SELECT trial. “This trial is the first to show a weight-management therapy in a rigorous randomized trial to reduce the risk of CV events associated with overweight and obesity, and now positions overweight and obesity as a modifiable risk factor for CVD” said Lincoff.
AHA 2023 "This is such a fascinating time in lipid therapeutics," says Karol Watson. She substantiates this by summarizing three late-breaking science studies with VERVE-101, lepodisiran and recaticimab.
AHA 2023 Deepak Gupta talks about the novel insights that the CARDIA-SSBP study provides on the effects of dietary sodium reduction on blood pressure.
In a Danish cohort study, individuals aged ≥70 years achieved a similar relative risk reduction of major vascular events with lipid-lowering therapy for primary prevention of CVD as those aged <70 years.
AHA 2023 In the SELECT trial, subcutaneous semaglutide 2.4 mg once weekly reduced the risk of CV events in patients with preexisting CVD and overweight or obesity who do not have diabetes.
AHA 2023 Apixaban reduced stroke or systemic embolism in patients with subclinical atrial fibrillation compared with aspirin in the ARTESIA trial. Apixaban increased the risk of major bleeding but there was no increase intracranial bleeding or fatal bleeding.
AHA 2023 In the absence of curative therapies for dementia, it was investigated whether a BP-lowering intervention can reduce the risk of dementia in patients with hypertension in China.